Yumanity Therapeutics

Kineta, Inc. is a clinical-stage biotechnology company, which develops immunotherapies for cancer patients. Its immuno-oncology focused platform aims at developing fully human antibodies to address the major mechanisms of cancer immune resistance. The company was founded by Shawn P. Iadonato and Charles L. Magness in 2008 and is headquartered in Seattle, WA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kineta, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies for cancer patients. Its pipeline includes immuno-suppression: aVISTA mAb and exhausted T-cells: aCD27 agonist mAb. The company was founded by Shawn P. Iadonato and Charles L. Magness in 2008 and is headquartered in Mercer Island, WA.

Yumanity Therapeutics (NASDAQ: YMTX ) stock is rocketing higher on Monday after the clinical-stage biopharmaceutical company announced a special dividend. According to a press release from the company, this special dividend will range in price from $1.34 to $1.43 per share.

Why Is Yumanity Therapeutics (YMTX) Stock Up Today?

Special dividend estimated to be in range of $1.34 to $1.43 per share

Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta

BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of the Company's recent corporate developments.

Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Special Meeting of stockholders to approve asset sale and merger to be held on December 13, 2022 Special Meeting of stockholders to approve asset sale and merger to be held on December 13, 2022

Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.

BOSTON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the filing of a registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”).

Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2022, and provided an overview of the Company's recent corporate developments.

Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating Yumanity Therapeutics, Inc. (NasdaqCM: YMTX) (the “Company”) regarding (1) the sale of its product candidate, YTX-7739 and Yumanity's unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV for $26 million in cash; and (2) Yumanity's proposed merger with Kineta, Inc., pursuant to which c

YUMANITY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Yumanity Therapeutics, Inc. - YMTX

Aeroclean Technologies

Missfresh Ltd

Check these penny stocks out for your watchlist right now The post Best Penny Stocks to Buy That Exploded Today? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy That Exploded Today? 3 to Watch

Yumanity Therapeutics (YMTX) stock is rocketing higher on Monday after announcing two definitive agreements. including a merger.

Why Is Yumanity Therapeutics (YMTX) Stock Up 50% Today?

Yumanity Therapeutics Inc (NASDAQ: YMTX) has agreed to sell its lead clinical-stage product candidate, YTX-7739, and discovery-stage neuroscience candidates to Janssen Pharmaceutica NV, a unit of Johnson & Johnson (NYSE: JNJ) for $26 million. Yumanity plans to.

Yumanity Therapeutics Shares Trading Higher Today - Read Here Why

Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV in a $26 million cash transaction

Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions

Yumanity (YMTX) delivered earnings and revenue surprises of -21.57% and 31.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Yumanity Therapeutics (YMTX) Reports Q1 Loss, Misses Revenue Estimates

BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2022, and provided an overview of the Company's recent corporate developments.

Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments

BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for full-year ended December 31, 2021 and provided an overview of the Company's recent corporate developments.

Yumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Developments

BOSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease, today announced that it is exploring strategic alternatives with the goal of enhancing shareholder value. The Company has engaged H.C. Wainwright as its exclusive financial advisor to assist in this process.

Yumanity Therapeutics Exploring Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring

BOSTON, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the grant to two employees of non-statutory stock options for the purchase of up to an aggregate of 6,000 shares of Yumanity's common stock. The options will vest over four years, with 25 percent of the shares vesting on the first anniversary of the employee's new hire date and the remainder vesting in equal monthly installments over the following three years. The options will have an exercise price of $2.19 per share, which is equal to the closing price of Yumanity's common stock on February 1, 2022, the grant date for the stock options, have a ten-year term and will be subject to the terms and conditions of the Yumanity Therapeutics, Inc. 2021 Inducement Plan and the terms and conditions of a stock option agreement covering the grant. The stock options were granted as inducements material to the employees entering into employment with Yumanity Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4).

Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The FDA has placed a partial clinical hold on Yumanity Therapeutics Inc's (NASDAQ: YMTX) multidose clinical trials of YTX-7739, currently being developed for Parkinson's disease.  The FDA has not halted all clinical programming and permits the Company's planned single-dose clinical trial to proceed.

Yumanity Shares Fall On FDA Hold On Multidose Trials In Parkinson's Disease

BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease, today announced that, in response to its IND application submitted in December 2021, it was notified via email by the U.S. Food and Drug Administration (FDA) that the FDA has placed a partial clinical hold on multidose clinical trials of YTX-7739, currently being developed for the treatment of Parkinson's disease. The FDA has not halted all clinical programming and is permitting the Company's planned single dose clinical trial to proceed. The partial clinical hold suspends initiation of multiple dose clinical trials in the U.S. until the FDA's questions have been addressed.

Yumanity Reports Partial Clinical Hold by U.S. FDA on Multidose Clinical Trials for YTX-7739

Yumanity achieves research milestone in its collaboration with Merck; Yumanity to receive $5 million milestone payment

Yumanity's Approach to Neurodegenerative Diseases Validated by Two External Collaborations

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference, being held virtually January 10-13, 2022.

Yumanity Therapeutics to Present at the H.C. Wainwright BioConnect Conference

BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will be presenting at the following investor conferences in November. He will discuss the results of the recently completed Phase 1b study of YTX-7739 in patients with Parkinson's disease and the development strategy going forward.

Yumanity Therapeutics to Present at Multiple Upcoming November Investor Conferences

Announced Successful Phase 1b trial for YTX-7739 in Parkinson's disease patients; YTX-7739 was well tolerated and demonstrated target engagement and favorable PK/PD and safety profiles

Yumanity Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

Yumanity Therapeutics Inc (NASDAQ: YMTX) reported topline data from Phase 1b trial of its lead product candidate, YTX-7739, for mild-to-moderate Parkinson's disease. The study achieved its primary endpoints.

Yumanity Therapeutics Stock Plunges After Parkinson's Trial Data

YTX-7739 demonstrated target engagement in Phase 1b clinical trial in patients with mild-to-moderate Parkinson's disease

Yumanity Therapeutics Announces Positive Top-Line Results of Phase 1b Clinical Trial for YTX-7739 in Patients with Parkinson's Disease; Company Plans to Advance Program to Phase 2

BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the grant to one new employee of a non-statutory stock option for the purchase of up to an aggregate of 30,000 shares of Yumanity's common stock. The option will vest over four years, with 25 percent of the shares vesting on the first anniversary of the employee's new hire date and the remainder vesting in equal monthly installments over the following three years. The option has an exercise price of $10.88 per share, which is equal to the closing price of Yumanity's common stock on September 1, 2021, the grant date for the stock option, has a ten-year term and is subject to the terms and conditions of the Yumanity Therapeutics, Inc. 2021 Inducement Plan and a stock option agreement covering the grant. The stock option was granted as an inducement material to the employee entering into employment with Yumanity Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4).

News for Yumanity Therapeutics Stock (YMTX)